ARVINAS, INC. - 8-K Filing
Arvinas announced plans to re-prioritize its drug development portfolio following a strategic review and intends to complete the Phase 1 monotherapy dose escalation trial for ARV-806 in patients with KRAS G12D mutations by 2026. The company expects cash reserves as of March 31, 2026, will fund operations through at least mid-2028 and is seeking an out-licensing agreement for further trials. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ARVN